[{"address1": "700 Quince Orchard Road", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 268 2000", "website": "https://global.novavax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 1543, "companyOfficers": [{"maxAge": 1, "name": "Mr. John Charles Jacobs M.B.A.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1329651, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Joseph Trizzino B.S., M.B.A.", "age": 64, "title": "President & COO", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 670550, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James Patrick Kelly C.F.A.", "age": 58, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 716175, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Casey", "age": 61, "title": "Executive VP, Chief Legal Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 137357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard P. Crowley", "age": 67, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Troy  Morgan Esq., J.D.", "age": 53, "title": "Senior VP, Deputy General Counsel & Chief Compliance Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erika S. Trahan", "title": "Associate Director of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian J. Watkins", "age": 61, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Silvia  Taylor M.B.A.", "title": "Executive VP and Chief Corporate Affairs & Advocacy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Walker M.D.", "title": "Senior VP & Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 5, "overallRisk": 5, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.novavax.com/go.cfm?do=Stock.GetQuote", "maxAge": 86400, "priceHint": 2, "previousClose": 8.18, "open": 8.2, "dayLow": 8.08, "dayHigh": 8.53, "regularMarketPreviousClose": 8.18, "regularMarketOpen": 8.2, "regularMarketDayLow": 8.08, "regularMarketDayHigh": 8.53, "beta": 2.125, "forwardPE": 14.419013, "volume": 2375240, "regularMarketVolume": 2375240, "averageVolume": 3962511, "averageVolume10days": 2892240, "averageDailyVolume10Day": 2892240, "bid": 8.17, "ask": 8.22, "bidSize": 1500, "askSize": 1300, "marketCap": 1311915008, "fiftyTwoWeekLow": 3.81, "fiftyTwoWeekHigh": 23.86, "priceToSalesTrailing12Months": 1.4820666, "fiftyDayAverage": 8.7412, "twoHundredDayAverage": 11.2402, "currency": "USD", "enterpriseValue": 664609088, "profitMargins": -0.3218, "floatShares": 141965553, "sharesOutstanding": 160184992, "sharesShort": 34935605, "sharesShortPriorMonth": 36917946, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.2181, "heldPercentInsiders": 0.08748, "heldPercentInstitutions": 0.60423, "shortRatio": 7.17, "shortPercentOfFloat": 0.272, "impliedSharesOutstanding": 160184992, "bookValue": -3.287, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -284857984, "trailingEps": -2.18, "forwardEps": -0.16, "lastSplitFactor": "1:20", "lastSplitDate": 1557446400, "enterpriseToRevenue": 0.751, "enterpriseToEbitda": -2.732, "52WeekChange": 0.98062956, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NVAX", "underlyingSymbol": "NVAX", "shortName": "Novavax, Inc.", "longName": "Novavax, Inc.", "firstTradeDateEpochUtc": 818173800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "cdb3cddb-5091-3918-86d6-9b4894e61c6c", "messageBoardId": "finmb_350381", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.19, "targetHighPrice": 25.0, "targetLowPrice": 9.0, "targetMeanPrice": 16.0, "targetMedianPrice": 15.5, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 909531008, "totalCashPerShare": 5.678, "ebitda": -243246000, "totalDebt": 262224992, "quickRatio": 0.89, "currentRatio": 0.935, "totalRevenue": 885193024, "revenuePerShare": 6.186, "returnOnAssets": -0.10759, "grossProfits": 115461000, "freeCashflow": -247394256, "operatingCashflow": -90881000, "revenueGrowth": -0.548, "grossMargins": 0.13044, "ebitdaMargins": -0.27479, "operatingMargins": -1.5360899, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]